Stand Up To Cancer partners with Johnson & Johnson to explore new treatment for AL amyloidosis

Post author:
Post published:November 12, 2024
Post category:uncategorized

Stand Up To Cancer (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a combination of two types of targeted therapies, teclistamab and daratumumab, to treat a rare disease called AL amyloidosis.

Empowering individuals with knowledge, fostering healthier lifestyles, and fostering a community dedicated to diabetes awareness and prevention. Together, we’re shaping a healthier future.

Helpful Links

Subscribe To Us

By submitting via this part of the website you are granting us permission to store and process your data according to our Standard privacy policy

UPCOMING EVENTS

You Might Also Like

Do environmental and occupational factors influence semen quality?

Steritas’ Pediatric Glucocorticoid Toxicity Index applied by Alder Hey Children’s NHS Foundation Trust and Liverpool Clinical Trials Centre in clinical trial to assess steroid toxicity in children with juvenile idiopathic arthritis

CDC study reveals critical gaps in hantavirus detection across the U.S. due to inconsistent testing standards

Helpful Links

Subscribe To Us